P. Dazzan
King's College London
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by P. Dazzan.
European Psychiatry | 2015
S. Rigucci; T. Reis Marques; M. Di Forti; Heather Taylor; Flavio Dell'Acqua; Valeria Mondelli; Stefania Bonaccorso; Andrew Simmons; Anthony S. David; Paolo Girardi; Carmine M. Pariante; R.M. Murray; P. Dazzan
Introduction High potency cannabis has been associated with greater risk, and earlier onset of psychosis. However, its effect on brain structure, particularly white matter (WM), has never been explored. Objectives and Aims To elucidate the interplay between cannabis potency, pattern of use (frequency and age of first use) and CC microstructure; in patients with first-episode psychosis (FEP) and healthy controls. Methods 56 FEP and 43 healthy controls underwent Diffusion-Tensor Imaging combined with WM mapping-tractography. CC was virtually dissected and segmented to calculate Fractional Anisotropy (FA), Mean Diffusivity (MD), Axial Diffusivity (AD) and Radial Diffusivity (RD) for each CC segment. Results High potency cannabis users had higher Total CC MD and Total CC AD than both low potency users and those who never used (p=0.009 and p=0.02 respectively). Daily users also had higher Total CC MD and Total CC AD than both occasional users and those who never used (p=0.02 and p=0.01 respectively). Furthermore, daily/highpotency users had higher Total CC MD than those who never used or used weekly [F(2,57)=4.7, p=0.01]. There was no effect of diagnosis or diagnosis X potency/patterns of use interactions; neither differences between users who started before the age of 15 and those who started later were detected, in any diffusivity measures. Conclusions Frequent use of high-potency cannabis significantly affects callosal microstructure, regardless of the presence of a psychotic disorder. Given the increased availability and use of high potency preparations in Europe, raising awareness about some of their detrimental effects is an important avenue to pursue.
British Journal of Psychiatry | 2006
Kimberlie Dean; Paul Fearon; Kevin Morgan; Gerard Hutchinson; K. Orr; Xavier Chitnis; John Suckling; R. Mallet; Julian Leff; Peter B. Jones; Robin M. Murray; P. Dazzan
Schizophrenia Bulletin | 2011
Simona A. Stilo; Craig Morgan; M. Di Forti; Alessandra Paparelli; Jennifer O'Connor; Manuela Russo; Ben Wiffen; Candice Joseph; Miriam Sirianni; Lucia Sideli; Sonija Luzi; Sonia Pintore; Anna Kolliakou; C. Pariante; P. Dazzan; Clare Flach; R.M. Murray
Schizophrenia Research | 2006
Helen L. Fisher; C. Morgan; Paul Fearon; Kevin Morgan; P. Dazzan; G. Doody; Tom Craig; Glynn Harrison; Julian Leff; Philip H. Jones; R.M. Murray
Schizophrenia Research | 2006
Arsime Demjaha; Kevin Morgan; C. Morgan; P. Dazzan; Sabine Landau; Kimberlie Dean; Paul Fearon; Julian Leff; Philip H. Jones; Robin M. Murray
Schizophrenia Research | 2008
B. Dimambro; Tuhina Lloyd; P. Dazzan; Kimberlie Dean; Paul Fearon; G. Doody; Jane Tarrant; Kevin Morgan; C. Morgan; Gerard Hutchinson; Julian Leff; Glynn Harrison; R.M. Murray; Peter B. Jones
Schizophrenia Research | 2006
C. Morgan; James B. Kirkbride; Julian Leff; Tom Craig; Gerard Hutchinson; Kwame McKenzie; Kevin Morgan; P. Dazzan; G. Doody; Philip H. Jones; R.M. Murray; Paul Fearon
European Neuropsychopharmacology | 2005
P. Dazzan; K.D. Morgan; K. Orr; G. Hutchinson; X. Chitnis; John Suckling; P. Fearon; Philip McGuire; R.M. Mallett; Peter B. Jones; J. Leff; Robin M. Murray
Schizophrenia Research | 2004
Arsime Demjaha; Kevin Morgan; P. Dazzan; N Kennedy; Kimberlie Dean; B Chapple; Paul Fearon; R Mallett; Julian Leff; Robin M. Murray
Schizophrenia Research | 2002
P. Dazzan; Kevin Morgan; John Suckling; Xavier Chitnis; Kenneth G. Orr; Paul Fearon; G Hutchison; J. Salvo; Ben Chapple; Philip H. Jones; R Mallett; Julian Leff; Robin M. Murray